There are innumerable choices of medicines for treatment of Diabetes II. As one of the most important emerging pathologies, with sufferers destined to skyrocket in number due to poor diet and exercise in the future, there is no shortage of medication to treat it.
And yet, the FDA is willing to review Avandia again, a drug that was banned in many European countries and restricted in the US, for the high risk of cardiac complications and damage to the heart.
Notwithstanding the innumerable lawsuits, and its own negative assessment of the high mortality rate incurred by patients on Avandia, the FDA has announced that it will review the drug again to see whether they should relax the strict guidelines now in place.
Apparently the review was prompted by a new study by the manufacturer that alleges proof of Avandia not being the cause of higher cardiac risk.
Although the research was done by Duke University, selective data management can easily reduce the negative outcome of a trial.
The truth appears to be simpler: the pharmaceutical company had one of its most profitable medications with Avandia, and like a dog with a bone, it's not about to let go.
In 2010, the FDA had slapped the medication with a serious restriction, following reports that the drug did increase significantly the risk of death from cardiac events. In fact millions of people used to take Avandia, and now only a few thousands do in the US. That may be about to change.
The FDA on its part is justifying the review by citing that the public interest is still great for the medication.
Op-Ed
Partial Source : France 24/ 6.5.13
No comments:
Post a Comment